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INTRODUCTION
Gout is one of the most common and complex causes of arthritis 
that can affect anyone.1,2 It is one of the most ancient medical con-
ditions known going back to references in Egypt in 2640 BC and 
Hippocrates writing about it in 400 BC.3-5 Gout occurs when there 
are deposits of urate monosodium crystals in the synovial fluid and 
other tissues causing the inflammation and intense pain of a gout 
attack. Urate monosodium crystals usually are associated with long-
term hyperuricemia that is triggered by several genetic factors as well 
as environmental factors such as the overconsumption of rich purine 
diets, alcohol, obesity, obesity-related disease, kidney disease, and 
certain medications.1,6-13 Risk factors for older patients include low-
dose aspirin, alcohol abuse, decreased renal function, and prolonged 
use of diuretics.14,15 
Advanced gout, also known as gouty tophi, are large, visible 
(masses) made up of urate crystals.5,16,17 The tophus is a cardinal sign 
and usually develops after 5-10 years of chronic undertreated gout 
with the olecranon bursa being one of the most affected areas.5,16,17 
Formation is caused by elevated serum uric acid levels due to neglect-
ed and poorly controlled gout.18,19 
Gouty tophi can develop anywhere. It can develop in peri-
articular soft tissues, sub-articular regions around bones, tendon 
sheaths, bursas, articular cartilage, and synovial tissues around 
flexor tendons.17,20 Gouty tophi have been identified in vocal cords, 
myocardium, heart valves, eyes, spinal cord, pancreatic tail, breast, 
penis, with a propensity to affect the helix of the ear.17,21,22 However, 
patients with multiple gouty tophi rarely are encountered because 
hyperuricemia can be treated effectively. The differential diagnosis of 
gouty tophi is broad, even though gout can be diagnosed clinically by 
elevated serum uric acid level; however, the concentration of serum 
uric acid may be within the normal limits and yet gouty tophi still can 
be developed.23-25 
This case was a patient who developed multiple gouty tophi over 
an extended period of time with increasing size of the masses while 
on medical treatment for his gout. The one mass of unique interest 
developed over the superficial anterior tibia just distal to the tibial 
tubercle and not in the patellar tendon, which is uncommon.
CASE REPORT
A 65-year-old obese male (height: 177.8 cm; weight: 123.3 kg; BMI: 
39.0 kg/m2) had advanced cardiac disease, and atrial fibrillation. He 
was on anticoagulation and presented to his primary care physician 
with intermittent pain and a mass on the left olecranon region of great-
er than 20 years. He was a non-smoker and drank no alcohol. His se-
rum uric acid level was 8.3 mg/dL. 
The patient was referred to an orthopedic clinic due to the mass. 
Physical examination revealed a prominent soft tissue mass that mea-
sured 30 cm x 12 cm x 4 cm, with a small laceration over the left dorsal 
proximal forearm, distal to the olecranon. The patient had no pain with 
active range of motion, but the lesion was painful with direct pressure 
over the subcutaneous mass. He complained of a soft tissue growth on 
his left elbow/forearm that had been enlarging slowly over the previous 
2 - 3 years.  He previously had undergone nonsurgical treatment that 
included needle aspiration of fluid from the soft tissue growth about 
10 years previously with no significant relief of the symptoms, at that 
time the patient was diagnosed with an olecranon bursa. No record of 
the fluid being sent for microbiological exam was noted.  He denied re-
cent trauma to the area but a small laceration was noted. He was not 
on any medications for gout but was on many medications for his heart 
disease and hypertension to include loop diuretics and anticoagulants.
Plain radiographs (Figure 1) of the left elbow showed mild spur for-
mation with a soft tissue mass. Computed tomography (CT) revealed a 
cystic accumulation with some calcific heterogenicity around the mar-
gins of the cystic tissue. CT was performed instead of using magnetic 
resonance imaging (MRI) because the patient had a pacemaker that 
prevented him from having a scan. From the radiographic images, he 
was diagnosed with an olecranon bursitis on his left elbow.
Figure 1. Radiographs of the mass on the patient's left elbow: (a) Anteroposte-
rior view, (b) Lateral view, (c) Oblique view.
Surgical resection of the mass was performed due to the pain 
when the patient would lean on it and the fact that there was a small 
laceration distal to the mass that would not heal. Operative report 
showed the mass was superficial to the fascia and periosteum with 
the size measured at 15 cm x 7 cm x 4.5 cm. It was fixed in formalin 
and the histopathology (Figure 2) revealed a gouty tophus with the 
presence of morphologic features and polarization characteristics 
(inflammation, fibrosis, and hemorrhage associated with abundant 
crystalline material). 
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Post-operatively, the patient developed a complex wound infec-
tion (skin loss and necrosis of the wound) ultimately undergoing 
multiple irrigations, debridements, and skin grafting procedures. 
With the patient’s multiple medical comorbidities including the need 
for anticoagulants, wound healing was prolonged. Four-months post-
operatively, the patient’s elbow showed no evidence of infection; the 
wound appeared clean and had healed. The patient had almost full 
range of motion at the time. His serum uric acid level was 6.9 mg/dL 
while being treated with allopurinol.
Figure 2. The histological examination of the mass on the left elbow. (A, B, 
C) Magnification view of eosinophilic amorphous material surrounded by 
histiocytic and chronic inflammation (x4, x10, and x20 power view). (D, E) 
Magnification view under polarizer showing needle shaped negatively birefrin-
gent crystals (10x and 20x power view).
Two and half years after the left elbow surgeries, the patient pre-
sented to the orthopedic clinic with two large soft tissue masses. One 
about the anterior aspect of the left tibia at approximately the junc-
tion of the proximal and mid-third of the tibia, and another one on 
the posterior aspect of the right elbow that had developed since his 
previous surgeries. The patient had no significant pain at either loca-
tion unless he leaned on either of the two areas. Exam of the left knee 
showed a soft tissue mass that measured approximately 6 cm x 6 cm 
over the front of the left tibia, medial and distal to the patellar tendon 
and tibial tubercle, and the right elbow soft tissue mass measuring 
about 8 cm across with no redness or breakdown of the skin. 
Plain radiographs of the right elbow showed a large soft tissue 
mass (Figures 3A - 3C). The left knee plain radiographs revealed 
medial compartmental narrowing and a large soft tissue prominence 
over the proximal tibia (Figures 3D - 3E). 
The patient’s health history had worsened, and it was significant 
for congestive heart failure, diabetes, atrial fibrillation, pacemaker/
defibrillator, previous myocardial infarction, hypertension, chronic 
warfarin and clopidogrel use, hyperlipidemia, sleep apnea, vari-
cosities, and gout. Due to his multiple co-morbidities and previous 
complications with surgery, the patient elected for non-surgical 
treatment even after discussion with the orthopedic surgeon who 
recommended excision of the masses before they broke down.
Figure 3. Radiographs of the mass on the patient. (A, B, C) right elbow and (D, 
E) left knee.
The patient accidentally bumped the mass over his anterior left 
tibia approximately 12 months after his last orthopedic office visit. 
His primary care provider had been trying to treat this conservatively 
without success. Due to the patient being on warfarin and clopidogrel, 
the mass had been oozing and bleeding since that time, wound care 
was not working, and the mass continued to drain. Approximately 2.5 
months later, the patient presented to another orthopedic surgeon 
with a large bleeding mass over the anterior left tibia. His serum uric 
acid level was 4.2 mg/dL which was below the defined serum urate 
level for hyperuricemia (> 6.8 mg/dL).26-28 Physical exam revealed 
a large skin lesion on the left anterior tibial region of the knee that 
had a black eschar formation that would bleed intermittently (Figure 
4). Plain radiographs showed moderate osteoarthritis involving the 
medial compartment with meniscal calcifications and a soft tissue 
mass about the anterior tibial region (Figure 5). Discussion with the 
patient centered on mass excision with irrigation and debridement 
due to concern for infection and the fact that it had not healed with 
2.5 months of conservative treatment.
Figure 4. Lateral and anterior views of the left tibial mass.
Figure 5. Radiographs of the mass on the patient's left knee.
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timeline to seek orthopedic care, the mass had compromised the skin 
leading to poor tissue for coverage. The mass was superficial, extending 
along the anterior-medial aspect of the proximal tibia just distal to the 
tibial tubercle. It measured 7 cm x 7 cm x 5 cm (Figure 6). The mass 
was sent in saline, and the histopathology revealed a gouty tophus with 
associated and marked necrosis, hematoma and suppurative inflamma-
tion, and no growth of organisms (Figure 7).
Figure 6. Resected mass from the left knee.
Figure 7. The histological examination of the mass on the left knee. (A) Proxi-
mal anterior tibia mass specimen showing surface skin ulceration. (B, C, D) 
Acutely and chronically inflamed fibrous tissue with nodular accumulation of 
amorphous pale pink material (x2, x4 and x10 power views). (E, F) Touch prep-
arations from fresh tissue show needle shaped negatively birefringent crystals.
The patient had difficulties healing the incision site and underwent 
wound care with a wound vac, and other modalities with no further 
operative intervention. Three months post-operatively, the patient’s 
wound showed no evidence of infection and the wound appeared 
clean with abundant healing granulation tissue (Figure 8). Due to 
the patient’s poor health conditions, his right elbow mass excision 
surgery has not been completed.
Figure 8. Three months follow up on the left knee.
DISCUSSION
The clinical course of this case provided two interesting findings. 
The first finding was the symptomatic gouty tophi appeared as a super-
ficial mass along the anterior tibia which is not common. The second 
finding was that the patient developed multiple gouty tophi over mul-
tiple extremities over a couple of years even with appropriate medical 
treatment to lower his uric acid levels.
It is rare to have gouty tophi formation since hyperuricemia can be 
treated effectively and the patient was on allopurinol that had lowered 
his uric acid levels. Hyperuricemia is defined as a serum urate level of 
approximately 6.8 mg/dL or higher.26-28 In this case, the patient’s uric 
acid levels dropped to 4.2 mg/dL which is below the defined level. Even 
with the medical treatment, the tophi continued to grow in size. This 
may have been related to his other comorbidities and medications that 
he was on which included loop diuretics. Loop diuretics (furosemide 
and bumetanide), thiazide diuretics (chlorthalidone and indapamide), 
and cyclosporine increase the risk of gout.29-32 Of note, serum uric acid 
levels in chronic tophaceous gout may not be conclusive of hyperurice-
mia in patients with diabetes. Therefore, his uric levels may have been 
falsely lower than noted leading the physician to believe that they were 
normal or at lower levels than they truly were.33 The patient also had 
changed his diet in hopes of modifying his risks for gout recurrence fol-
lowing his providers’ recommendations.
Surgical intervention of gouty tophi rarely is needed due to medi-
cal management.  Surgery is indicated if the tophi are painful, shows 
impending skin necrosis, infection, ulcerating wound, tendon impair-
ment, mechanical impairment, nerve compression, and joint destruc-
tion.34-36 Surgery can be challenging because of wound complica-
tions.37,38 Ochoa et al.39 suggested that inflammatory changes of the 
lobular subcutaneous tissue can be triggered and perpetuated by the 
arterial blood supply disruption caused by the monosodium urate 
crystals thus rending tissue vulnerable to deposits. They also believed 
that some microtrauma of the walls of terminal blood vessels as well 
as communication loss between the vessels and the dermis occurred, 
making the tissue vulnerable.
Gouty tophi may appear at intra- or extra-articular locations.40-45 It 
can be in the subcutaneous tissue. It mostly affects peripheral joints, 
but can involve the extensor tendons of the knee. Bone erosions at the 
sites of tophi formation are common, but superficial gouty tophi ap-
pearing along the anterior tibia is rare when it does not extend from the 
interarticular knee joint or from the tendon. Usually, these gouty tophi 
do not cause the patient any pain unless they become acutely inflamed, 
but they can cause problems when trying to kneel on them. 
What is the reason for the higher complication rates? Is it related 
to waiting too long and having to deal with the aftermath of an open 
wound and poor skin coverage?  Would it be better to remove the tophi 
earlier in the disease process when they have not eroded through the 
skin? Gouty tophi and its pathophysiology potentially can lead to the 
poor healing but waiting until the mass is so large is another problem. 
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Skin under tension and thinned out due to the size is a problem no 
matter the etiology of the mass.
On a final note, it is important to consider how the pathological 
specimen is sent to the pathologist. The correct fixative is important 
and the specimens should be submitted in alcohol fixative because the 
monosodium urate crystals in gout dissolve away in formalin and are 
lost from hematoxylin and eosin (H&E) stained sections.46,47 Physicians 
also should consider having cultures done on the specimen as well as a 
crystal analysis.
CONCLUSION
This report represented a unique case of how gouty tophi can de-
velop at multiple joint locations over a short time period even with 
appropriate medical treatment, and how one of these tophi devel-
oped in the superficial tissues of the anterior tibia outside of any 
joint or tendon. Although gouty tophi are not life threatening, it has a 
significant impact on the quality of life. Intervening sooner medically 
may be a benefit for the patient with the hope that patient compli-
ance with therapeutics may have an important impact on prognosis 
and avert surgical intervention. Nevertheless, lab values may mis-
represent true uric acid levels. Gouty tophi may need to be removed 
sooner if therapeutics have not changed the progression and earlier 
involvement with the surgeon is warranted.
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